IDEAYA Biosciences Files 8-K Update

TL;DR

IDEAYA dropped an 8-K update on clinical programs and strategy.

AI Summary

On June 3, 2024, IDEAYA Biosciences, Inc. filed an 8-K report. The filing indicates that the company is providing an update on its clinical programs and business strategy. No specific financial figures or new material agreements were detailed in this particular filing.

Why It Matters

This 8-K filing signals an update from IDEAYA Biosciences regarding their ongoing clinical trials and strategic direction, which could influence investor perception of their drug development progress.

Risk Assessment

Risk Level: low — This filing is a routine update and does not appear to contain any immediately adverse or significantly positive material information.

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — Registrant
• June 3, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq

Filing Documents

• idya-20240603.htm (8-K) — 47KB
• 0000950170-24-067644.txt ( ) — 165KB
• idya-20240603.xsd (EX-101.SCH) — 28KB
• idya-20240603_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. Clinical Updates On June 3, 2024, IDEAYA Biosciences, Inc. (the "Company") announced clinical data from the ongoing investigator-sponsored Phase 2 trial of darovasertib, the Company's oral, small molecular inhibitor of protein kinase C (or PKC), as neoadjuvant/adjuvant treatment in uveal melanoma (or UM). The clinical data from the trial were included in an oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting by Anthony Joshua, MBBS, PhD, FRACP, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital in Sydney, and the lead principal investigator of the Phase 2 study. The Company also announced preliminary clinical data from its Phase 2 trial of darovasertib for neoadjuvant UM. ASCO Clinical Data from Investigator-Sponsored Phase 2 Trial: Fifteen patients planned for enucleation with localizedUM were treated with darovasertib 300mg twice daily. An initial safety cohort of three patients were treated for one month, and the remaining 12 patients were treated in an expansion cohort for up to six months as neoadjuvant treatment prior to their primary intervention (enucleation, plaque brachytherapy or external beam radiotherapy (EBRT)) across three Australian centers. As of the database lock on May 14, 2024, 13 patients had completed neoadjuvant treatment, 11 patients received adjuvant darovasertib after primary treatment of their UM, with five patients completing the planned six months of therapy. As of May 14, 2024, 75% (9 out of 12 enucleation patients) had confirmed Eye Saved (i.e., converted to plaque brachytherapy or EBRT) and approximately 67% (8 out of 12 enucleation patients) observed greater than 30% tumor shrinkage (maximum volume change) after 6 months. Median tumor shrinkage (maximum volume change) in 12 enucleation patients was approximately 47% after 6 months. The darovasertib monotherapy neoadjuvant treatment had a manageable adverse event (AE) profile wit

Forward-Looking Statements

Forward-Looking Statements Certain statements contained herein are forward-looking statements including, but not limited to, statements related to (i) expectations regarding the clinical activity profile and potential advantages of the Company's clinical programs, (ii) the translation of preliminary clinical trial results into future clinical trial results, and (iii) the enrollment of clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, serious adverse events, undesirable side effects or unexpected characteristics of drug development programs, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the ||| Company in general, see the Company's Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission. |||

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: June 3, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer |||

View Full Filing

View this 8-K filing on SEC EDGAR